NA
UTHR icon

Navellier & Associates’s United Therapeutics UTHR Stock Holding History

Navellier & Associates’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,348
Closed -$601K – 328
2022
Q1 		$601K Sell
3,348
-37
-1% -$7.05K 0.1% 171
2021
Q4 		$731K Buy
3,385
+816
+32% +$160K 0.11% 164
2021
Q3 		$474K Buy
+2,569
New +$506K 0.07% 203

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Navellier & Associates's UTHR Position: Q2 2022 in Review

Navellier & Associates sold out of United Therapeutics (UTHR) in Q2 2022, closing a stake of 3,348 shares — an estimated $601K sold.

Navellier & Associates first reported a position in UTHR in Q3 2021 and held it in 3 quarters. The position peaked at $731K in Q4 2021. 472 funds tracked by Wall St. Rank hold UTHR as of Q2 2022.

  • Navellier & Associates reported no remaining United Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Navellier & Associates sold 3,348 United Therapeutics shares in Q2 2022, an estimated $601K.
  • Navellier & Associates first reported a position in United Therapeutics in Q3 2021 and held it in 3 quarters.
  • Navellier & Associates's United Therapeutics position peaked at $731K in Q4 2021.
  • 472 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2022.

Based on Navellier & Associates's 13F filing for Q2 2022, filed 12 Aug 2022.